Marc Feldmann

List of Publications by Citations

268 papers	31,806 citations	85 h-index	174 g-index
282 ext. papers	35,138 ext. citations	12.2 avg, IF	7.09 L-index

#	Paper	IF	Citations
268	Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *New England Journal of Medicine*, **2000**, 343, 1594-602	59.2	2590
267	Role of cytokines in rheumatoid arthritis. *Annual Review of Immunology*, **1996**, 14, 397-440	34.7	2051
266	Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet, The*, **1999**, 354, 1932-9	40	1960
265	Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. *Annual Review of Immunology*, **2001**, 19, 163-96	34.7	1068
264	An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nature Medicine*, **2020**, 26, 1636-1643	50.5	895
263	Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. *Arthritis and Rheumatism*, **1993**, 36, 1681-90		874
262	IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. *Nature Immunology*, **2011**, 12, 231-8	19.1	818
261	Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. *European Journal of Immunology*, **1988**, 18, 1797-801	6.1	686
260	Development of anti-TNF therapy for rheumatoid arthritis. *Nature Reviews Immunology*, **2002**, 2, 364-71	36.5	524
259	Role of interleukin-1beta in postoperative cognitive dysfunction. *Annals of Neurology*, **2010**, 68, 360-8	9.4	484
258	Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 20518-22	11.5	466
257	Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. *Nature Medicine*, **2003**, 9, 1245-50	50.5	453
256	HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. *Nature*, **1987**, 326, 304-6	50.4	430
255	Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. *Nature*, **1984**, 312, 639-41	50.4	399
254	Resolving postoperative neuroinflammation and cognitive decline. *Annals of Neurology*, **2011**, 70, 986-995	9.4	362
253	Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. *Lancet, The*, **2020**, 395, 1407-1409	40	361
252	Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. *Immunological Reviews*, **2010**, 233, 34-54	11.3	350

251	Alarmins: awaiting a clinical response. *Journal of Clinical Investigation*, **2012**, 122, 2711-9	15.9	347
250	Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. *European Journal of Immunology*, **1997**, 27, 624-32	6.1	328
249	Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. *Arthritis and Rheumatism*, **2002**, 46, 31-41		314
248	Macrophage heterogeneity in the context of rheumatoid arthritis. *Nature Reviews Rheumatology*, **2016**, 12, 472-85	8.1	310
247	Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. *Arthritis and Rheumatism*, **1998**, 41, 1258-65		305
246	Anti-TNF therapy: past, present and future. *International Immunology*, **2015**, 27, 55-62	4.9	294
245	Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. *Nature Reviews Rheumatology*, **2009**, 5, 578-82	8.1	275
244	Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. *European Journal of Immunology*, **1996**, 26, 1511-8	6.1	268
243	The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. *Journal of Experimental Medicine*, **1971**, 134, 103-19	16.6	263
242	Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. *Immunological Reviews*, **2008**, 223, 7-19	11.3	262
241	TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 1585-90	11.5	258
240	Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 5634-9	11.5	251
239	Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. *European Journal of Immunology*, **1990**, 20, 2141-4	6.1	249
238	Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin. *Journal of Experimental Medicine*, **1972**, 136, 737-60	16.6	245
237	Design of effective immunotherapy for human autoimmunity. *Nature*, **2005**, 435, 612-9	50.4	217
236	Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. *European Journal of Immunology*, **1996**, 26, 2320-8	6.1	214
235	Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. *European Journal of Immunology*, **1994**, 24, 2040-8	6.1	212
234	Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. *International Immunology*, **2001**, 13, 675-83	4.9	196

233	VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. *Journal of Cell Science*, **2003**, 116, 665-74	5.3	182
232	Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. *Immunological Reviews*, **1995**, 144, 195-223	11.3	179
231	Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. *Advances in Immunology*, **1997**, 64, 283-350	5.6	173
230	Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. *European Journal of Immunology*, **1994**, 24, 2699-705	6.1	164
229	Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. *Blood*, **2004**, 103, 2229-37	9.2	161
228	Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. *European Journal of Immunology*, **1991**, 21, 1635-9	6.1	159
227	Cell-mediated immune response in vitro. 3. The requirement for macrophages in cytotoxic reactions against cell-bound and subcellular alloantigens. *Journal of Experimental Medicine*, **1972**, 136, 331-43	16.6	154
226	Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. *Immunological Reviews*, **2004**, 202, 250-65	11.3	152
225	NF-B as a target for modulating inflammatory responses. *Current Pharmaceutical Design*, **2012**, 18, 5735-45	3.3	149
224	The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. *American Journal of Pathology*, **2007**, 170, 518-25	5.8	149
223	Cell interactions in the immune response in vitro. 3. Specific collaboration across a cell impermeable membrane. *Journal of Experimental Medicine*, **1972**, 136, 49-67	16.6	147
222	Cell interactions in the immune response in vitro. IV. Comparison of the effects of antigen-specific and allogeneic thymus-derived cell factors. *Journal of Experimental Medicine*, **1972**, 136, 722-36	16.6	145
221	Cytokines and anti-cytokine biologicals in autoimmunity: present and future. *Cytokine and Growth Factor Reviews*, **2002**, 13, 299-313	17.9	139
220	Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. *Laboratory Investigation*, **2000**, 80, 1195-205	5.9	136
219	Unexpected protective role for Toll-like receptor 3 in the arterial wall. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 2372-7	11.5	134
218	Induction of immunity and tolerance in vitro by hapten protein conjugates. I. The relationship between the degree of hapten conjugation and the immunogenicity of dinitrophenylated polymerized flagellin. *Journal of Experimental Medicine*, **1972**, 135, 735-53	16.6	133
217	Historical review: Cytokines as therapeutics and targets of therapeutics. *Trends in Pharmacological Sciences*, **2004**, 25, 201-9	13.2	130
216	T-cell lines producing antigen-specific suppressor factor. *Nature*, **1978**, 274, 477-80	50.4	128

215	Antibody-mediated suppression of the immune response in vitro. I. Evidence for a central effect. *Journal of Experimental Medicine*, **1970**, 131, 247-74	16.6	125
214	Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. *Circulation*, **2009**, 120, 2462-9	16.7	122
213	Therapeutic antibodies elicited by immunization against TNF-alpha. *Nature Biotechnology*, **1999**, 17, 666-9	44.5	122
212	Cell interactions in the immune response in vitro. II. The requirement for macrophages in lymphoid cell collaboration. *Journal of Experimental Medicine*, **1972**, 135, 1049-58	16.6	122
211	A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. *Arthritis and Rheumatism*, **2004**, 50, 985-98		120
210	A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. *Journal of Immunology*, **2004**, 173, 6928-37	5.3	118
209	Role of pro-inflammatory cytokines in rheumatoid arthritis. *Seminars in Immunopathology*, **1998**, 20, 133-47		116
208	Essential requirement for major histocompatibility complex recognition in T-cell tolerance induction. *Nature*, **1984**, 308, 72-4	50.4	112
207	Specific collaboration between T and B lymphocytes across a cell impermeable membrane in vitro. *Nature: New Biology*, **1972**, 237, 13-5		112
206	A human suppressor T cell clone which recognizes an autologous helper T cell clone. *Nature*, **1982**, 300, 456-8	50.4	110
205	The role of macrophages in the generation of T helper cells. III. Influence of macrophage-derived factors in helper cell induction. *European Journal of Immunology*, **1975**, 5, 759-66	6.1	107
204	Role of macrophages in in vitro induction of T-helper cells. *Nature*, **1975**, 254, 352-4	50.4	106
203	Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. *Nature*, **1975**, 258, 614-6	50.4	105
202	Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. *Science Immunology*, **2020**, 5,	28	105
201	Antibody-mediated suppression of the immune response in vitro. II. A new approach to the phenomenon of immunological tolerance. *Journal of Experimental Medicine*, **1970**, 132, 31-43	16.6	104
200	Many cytokines are very useful therapeutic targets in disease. *Journal of Clinical Investigation*, **2008**, 118, 3533-6	15.9	104
199	Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. *Cellular Immunology*, **1972**, 4, 39-50	4.4	103
198	Monospecificity of bone marrow-derived lymphocytes. *Journal of Experimental Medicine*, **1973**, 137, 1024-30	16.6	102

197	Role of macrophages in the generation of T helper cells. IV. Nature of genetically related factor derived from macrophages incubated with soluble antigens. *European Journal of Immunology*, **1976**, 6, 365-72	6.1	101
196	Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. *European Journal of Immunology*, **2001**, 31, 1883-93	6.1	99
195	Cytokines in autoimmunity. *Current Opinion in Immunology*, **1996**, 8, 872-7	7.8	97
194	Functional expression of HLA-DP genes transfected into mouse fibroblasts. *Nature*, **1985**, 313, 61-4	50.4	94
193	The role of macrophages in the generation of T-helper cells. I. The requirement for macrophages in helper cell induction and characteristics of the macrophage-T cell interaction. *Cellular Immunology*, **1975**, 19, 356-67	4.4	94
192	Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E928-37	11.5	92
191	Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. *Journal of Immunology*, **2000**, 165, 7240-5	5.3	92
190	Developments in therapy with monoclonal antibodies and related proteins. *Clinical Medicine*, **2017**, 17, 220-232	1.9	91
189	IRF5 controls both acute and chronic inflammation. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 11001-6	11.5	91
188	Cytokines in autoimmunity. *Current Opinion in Immunology*, **1992**, 4, 754-9	7.8	91
187	Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. *Journal of Immunology*, **2001**, 166, 4124-30	5.3	87
186	Human T cells from autoimmune and normal individuals can produce tumor necrosis factor. *European Journal of Immunology*, **1987**, 17, 1807-14	6.1	85
185	Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. *Lancet Rheumatology, The*, **2020**, 2, e653-e655	14.2	85
184	IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. *Journal of Experimental Medicine*, **2010**, 207, 2081-8	16.6	84
183	Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. *European Journal of Immunology*, **1992**, 22, 1907-12	6.1	84
182	Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. *Arthritis and Rheumatology*, **2014**, 66, 2728-38	9.5	82
181	Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. *Journal of Pharmacology and Experimental*	4.7	82
180	Suppressor cell induction in vitro. II. Cellular requirements of suppressor cell induction. *European Journal of Immunology*, **1976**, 6, 302-5	6.1	82

179	Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?. *Journal of Immunology*, **2010**, 185, 791-4	5.3	81
178	Suppressor cell induction in vitro. I. Kinetics of induction of antigen-specific suppressor cells. *European Journal of Immunology*, **1976**, 6, 296-301	6.1	81
177	Role of C3 in in vitro lymphocyte cooperation. *Nature*, **1974**, 249, 159-61	50.4	81
176	Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. *European Journal of Immunology*, **1999**, 29, 2205-12	6.1	80
175	B Cell heterogeneity - difference in the size of B lymphocytes responding to T dependent and T independent antigens. *Cellular Immunology*, **1975**, 18, 88-97	4.4	80
174	Anti-TNF therapy: where have we got to in 2005?. *Journal of Autoimmunity*, **2005**, 25 Suppl, 26-8	15.5	77
173	Cell-mediated immune response in vitro. I. A new in vitro system for the generation of cell-mediated cytotoxic activity. *Cellular Immunology*, **1972**, 3, 405-20	4.4	75
172	NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts. *Journal of Immunology*, **2001**, 167, 5895-903	5.3	74
171	Are CD4+ Th1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN-gamma or IL-2 determines their function. *International Immunology*, **1995**, 7, 1287-94	4.9	74
170	Low-dose TNF augments fracture healing in normal and osteoporotic bone by up-regulating the innate immune response. *EMBO Molecular Medicine*, **2015**, 7, 547-61	12	73
169	Transforming growth factor beta induces the production of interleukin 6 by human peripheral blood mononuclear cells. *Cytokine*, **1990**, 2, 211-6	4	73
168	Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. *Journal of Immunology*, **2008**, 181, 8002-9	5.3	72
167	Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. *Joint Bone Spine*, **2002**, 69, 12-8	2.9	70
166	Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 13033-8	11.5	68
165	Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. *Current Opinion in Pharmacology*, **2007**, 7, 412-7	5.1	68
164	Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 1167-79	12.7	67
163	TNF alpha is an effective therapeutic target for rheumatoid arthritis. *Annals of the New York Academy of Sciences*, **1995**, 766, 272-8	6.5	67
162	Interleukin 7 is a growth factor for mature human T cells. *European Journal of Immunology*, **1990**, 20, 425-8	6.1	67

161	Direct triggering of B lymphocytes by insolubilized antigen. *European Journal of Immunology*, **1974**, 4, 591-7	6.1	67
160	Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. *Cytokine*, **2004**, 28, 35-47	4	66
159	In vitro studies on H-2-linked unresponsiveness to synthetic polypeptides. III. Production of an antigen-specific T helper cell factor to (T,G)-A--L. *European Journal of Immunology*, **1977**, 7, 417-21	6.1	66
158	Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. *Molecular Immunology*, **2008**, 45, 2446-54	4.3	62
157	TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. *European Journal of Immunology*, **2002**, 32, 2037-45	6.1	62
156	Interleukin 4 induces interleukin 6 production by endothelial cells: synergy with interferon-gamma. *European Journal of Immunology*, **1991**, 21, 97-101	6.1	62
155	Interleukin 7 (murine pre-B cell growth factor/lymphopoietin 1) stimulates thymocyte growth: regulation by transforming growth factor beta. *European Journal of Immunology*, **1989**, 19, 783-6	6.1	62
154	Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. *Biochemical and Biophysical Research Communications*, **2006**, 340, 984-94	3.4	61
153	Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. *Blood*, **2003**, 101, 983-91	2.2	61
152	The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. *Best Practice and Research in Clinical Rheumatology*, **2004**, 18, 59-80	5.3	61
151	Induction of immunity and tolerance in vitro by hapten protein conjugates. II. Carrier independence of the response to dinitrophenylated polymerized flagellin. *European Journal of Immunology*, **1972**, 2, 130-7	6.1	61
150	Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. *Molecular Medicine*, **2007**, 13, 40-58	6.2	57
149	CD44 involvement in experimental collagen-induced arthritis (CIA). *Journal of Autoimmunity*, **1999**, 13, 39-47	15.5	57
148	Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to G. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E4463-E4472	11.5	55
147	Stimulation of the α7 nicotinic acetylcholine receptor protects against neuroinflammation after tibia fracture and endotoxemia in mice. *Molecular Medicine*, **2015**, 20, 667-75	6.2	55
146	Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. *Journal of Rheumatology*, **2007**, 34, 523-33	4.1	54
145	Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon-gamma and tumor necrosis factor-alpha. *European Journal of Immunology*, **1989**, 19, 189-92	6.1	53
144	Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. *Cytokine*, **1995**, 7, 759-70	4	52

143	The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. *Med*, **2020**, 1, 90-102	32.7	51
142	Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. *Current Opinion in Biotechnology*, **2004**, 15, 557-63	11.4	51
141	Suppressor cell induction in vitro. III. Antigen-specific suppression by supernatants of suppressor cells. *European Journal of Immunology*, **1977**, 7, 310-4	6.1	50
140	Induction of immunity and tolerance to the dinitrophenyl determinant in vitro. *Nature: New Biology*, **1971**, 231, 21-3		50
139	Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 1243-52	12.7	49
138	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. *Journal of Biological Chemistry*, **2018**, 293, 2422-2437	5.4	48
137	Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. *Journal of Immunology*, **2010**, 185, 3694-701	5.3	48
136	Translating molecular insights in autoimmunity into effective therapy. *Annual Review of Immunology*, **2009**, 27, 1-27	34.7	48
135	Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. *Progress in Growth Factor Research*, **1992**, 4, 247-55		46
134	Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. *Cytokine*, **1990**, 2, 60-7	4	46
133	Cell interactions in the immune response in vitro. I. Metabolic activities of T cells in a collaborative antibody response. *European Journal of Immunology*, **1972**, 2, 213-24	6.1	46
132	Human macrophages induced in vitro by macrophage colony-stimulating factor are deficient in IL-12 production. *European Journal of Immunology*, **1998**, 28, 2498-507	6.1	45
131	Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. *European Journal of Immunology*, **1998**, 28, 3904-16	6.1	45
130	Tolerance, enhancement and the regulation of interactions between T cells, B cells and macrophages. *Immunological Reviews*, **1972**, 13, 3-34	11.3	45
129	Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. *Arthritis and Rheumatism*, **2001**, 44, 1215-24		44
128	T cell suppression in vitro. II. Nature of specific suppressive factor. *European Journal of Immunology*, **1974**, 4, 667-74	6.1	44
127	Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 16717-22	11.5	43
126	Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. *Journal of Immunology*, **2000**, 164, 2776-81	5.3	43

125	Mechanisms at the cellular level during induction of high zone tolerance in vitro. *Cellular Immunology*, **1972**, 5, 130-6	4.4	43
124	An inflammatory cytokine signature helps predict COVID-19 severity and death **2020**,		43
123	Effective targeting of the tumor microenvironment for cancer therapy. *Anticancer Research*, **2012**, 32, 1203-12	2.3	43
122	CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. *Arthritis and Rheumatism*, **2008**, 58, 1038-43		41
121	CD40 ligation induces macrophage IL-10 and TNF-alpha production: differential use of the PI3K and p42/44 MAPK-pathways. *Cytokine*, **2001**, 16, 131-42	4	41
120	Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. *European Journal of Immunology*, **1994**, 24, 1879-85	6.1	41
119	Induction of specific helper cells in vitro. *Nature: New Biology*, **1973**, 245, 285-6		41
118	Preclinical target validation using patient-derived cells. *Nature Reviews Drug Discovery*, **2015**, 14, 149-50	64.1	40
117	SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. *Arthritis and Rheumatism*, **2010**, 62, 2249-61		40
116	Reduction of cPLA2alpha overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis. *European Journal of Immunology*, **2008**, 38, 2905-15	6.1	39
115	Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver. *Journal of Immunology*, **2001**, 166, 5970-8	5.3	39
114	Serological analysis of antigen-specific helper factors specific for poly-L(Tyr, Glu)-poly-DLAla--poly-LLys [(T, G)-A--L] and L Glu60-LAla30-LTyr10 (GAT). *European Journal of Immunology*, **1979**, 9, 501-6	6.1	39
113	Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis. *Arthritis and Rheumatism*, **2011**, 63, 2617-29		38
112	Role of epitope density in the induction of immunity and tolerance with thymus-independent antigens. I. Studies with 2,4-dinitrophenyl conjugates in vitro. *European Journal of Immunology*, **1975**, 5, 537-41	6.1	38
111	T cell suppression in vitro. I. Role in regulation of antibody responses. *European Journal of Immunology*, **1974**, 4, 660-6	6.1	38
110	Monoclonal antibodies in immune and inflammatory diseases. *Current Opinion in Biotechnology*, **2002**, 13, 615-20	11.4	37
109	Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. *Arthritis and Rheumatism*, **2003**, 48, 839-45		37
108	Long-term human T-helper lines producing specific helper factor reactive to influenza virus. *Nature*, **1981**, 294, 166-8	50.4	37

107	Humoral and cell mediated responses in vitro of spleen cells from mice with thymic aplasia (nude mice). *The Australian Journal of Experimental Biology and Medical Science*, **1972**, 50, 651-60		37
106	Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 6056-6066	11.5	36
105	Selective use of TRAM in lipopolysaccharide (LPS) and lipoteichoic acid (LTA) induced NF-kappaB activation and cytokine production in primary human cells: TRAM is an adaptor for LPS and LTA signaling. *Journal of Immunology*, **2007**, 178, 2148-54	5.3	36
104	The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy. *Journal of Immunology*, **2001**, 166, 4973-80	5.3	36
103	Interleukin-4 inhibits kappa light chain expression and NF kappa B activation but not I kappa B alpha degradation in 70Z/3 murine pre-B cells. *European Journal of Immunology*, **1995**, 25, 2961-6	6.1	36
102	Antigen-specific T cell unresponsiveness in cloned helper T cells mediated via the CD2 or CD3/Ti receptor pathways. *European Journal of Immunology*, **1987**, 17, 1641-4	6.1	36
101	Induction of immunity and tolerance in vitro by hapten protein conjugates. 3. Hapten inhibition studies of antigen binding to B cells in immunity and tolerance. *Journal of Experimental Medicine*, **1972**, 136, 532-45	16.6	36
100	TNF receptor 2 signaling prevents DNA methylation at the promoter and prevents pathogenic conversion of regulatory T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 21666-21672	11.5	35
99	Anti-TNF Therapy. *Microbiology Spectrum*, **2016**, 4,	8.9	34
98	Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?. *Arthritis and Rheumatology*, **2015**, 67, 2283-91	9.5	34
97	The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity. *Annals of the Rheumatic Diseases*, **2010**, 69, 1519-26	2.4	34
96	The mechanism of antigenic competition. I. The macrophage as a site of a reversible block of T-B lymphocyte collaboration. *European Journal of Immunology*, **1973**, 3, 711-7	6.1	34
95	RelB/p50 regulates TNF production in LPS-stimulated dendritic cells and macrophages. *Cytokine*, **2013**, 61, 736-40	4	33
94	Interleukin-7 activates human naive CD4+ cells and primes for interleukin-4 production. *European Journal of Immunology*, **1997**, 27, 633-40	6.1	32
93	Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. *Cytokine*, **1993**, 5, 205-12	4	32
92	Relationship between antigen and antibody-induced suppression of immunity. *Immunological Reviews*, **1972**, 8, 76-103	11.3	32
91	Contrasting effects of interferon gamma and interleukin 4 on responses of human vascular endothelial cells to tumour necrosis factor alpha. *Cytokine*, **1992**, 4, 470-8	4	31
90	A conversation with Marc Feldmann. Interviewed by Ushma S. Neill. *Journal of Clinical Investigation*, **2014**, 124, 1-2	15.9	31

89	T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. *Journal of Leukocyte Biology*, **2002**, 71, 659-68	6.5	31
88	OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 2289-94	11.5	30
87	Anti- TNF Therapy of Rheumatoid Arthritis: What Can We Learn about Chronic Disease?. *Novartis Foundation Symposium*, **2008**, 53-73		30
86	Cloning, expression and cross-linking analysis of the murine p55 tumor necrosis factor receptor. *European Journal of Immunology*, **1991**, 21, 1649-56	6.1	30
85	Immune response (Ir) genes expressed at macrophage-B lymphocyte interactions. *Nature*, **1978**, 273, 664-6	50.4	30
84	Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. *Arthritis and Rheumatism*, **2013**, 65, 2262-73		29
83	Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. *Current Opinion in Immunology*, **2004**, 16, 780-6	7.8	29
82	Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial. *EBioMedicine*, **2018**, 33, 282-288	8.8	28
81	Inhibition of T cell proliferation by antibodies to synthetic peptides. *European Journal of Immunology*, **1984**, 14, 153-7	6.1	28
80	T-T interaction in the generation of helper cells in vitro. *Nature*, **1975**, 256, 741-3	50.4	28
79	Mechanisms of B-cell tolerance. *British Medical Bulletin*, **1976**, 32, 141-6	5.4	28
78	Lack of requirement for cell cooperation in the antibody response to DNP conjugated to levan. *Cellular Immunology*, **1975**, 16, 106-14	4.4	27
77	TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-B pathways and signals TRAF2 protein degradation in macrophages. *Cellular Signalling*, **2014**, 26, 683-90	4.9	26
76	Two-gene control of T-helper cell induction. *Nature*, **1976**, 263, 601-4	50.4	26
75	Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications. *Therapeutic Advances in Musculoskeletal Disease*, **2015**, 7, 206-19	3.8	25
74	Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. *Seminars in Immunopathology*, **1994**, 16, 327-36		25
73	Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA. *Biochemical and Biophysical Research Communications*, **1988**, 153, 1144-51	3.4	25
72	Dynamic aspects of antigen binding to B cells in immune induction. *Nature: New Biology*, **1972**, 237, 3-5		25

71	Tolerance induction to a hapten protein conjugate in vivo: are suppressor T cells involved. *European Journal of Immunology*, **1974**, 4, 768-71	6.1	25
70	Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. *Immunology*, **2014**, 142, 581-93	7.8	24
69	Alveolar macrophages and T cells from sarcoid, but not normal lung, are permissive to adenovirus infection and allow analysis of NF-kappa b-dependent signaling pathways. *American Journal of Respiratory Cell and Molecular Biology*, **2001**, 25, 141-9	5.7	24
68	What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?. *International Archives of Allergy and Immunology*, **1996**, 111, 362-5	3.7	23
67	Enrichment of antigen-specific helper and suppressor T cells. *Nature*, **1976**, 260, 324-7	50.4	23
66	Post-transcriptional control of IL-1 gene expression in the acute monocytic leukemia line THP-1. *Biochemical and Biophysical Research Communications*, **1988**, 156, 830-9	3.4	22
65	TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. *Cytokine*, **1994**, 6, 616-23	4	21
64	Synergism of glucocorticoids with granulocyte macrophage colony stimulating factor (GM-CSF) but not interferon gamma (IFN-gamma) or interleukin-4 (IL-4) on induction of HLA class II expression on human monocytes. *Cytokine*, **1992**, 4, 287-97	4	21
63	The role of receptors for tumour necrosis factor-alpha in the induction of human polymorphonuclear neutrophil chemiluminescence. *Immunology Letters*, **1996**, 53, 45-50	4.1	20
62	Route of monocyte differentiation determines their cytokine production profile: CD40 ligation induces interleukin 10 expression. *Cytokine*, **2000**, 12, 1496-505	4	19
61	An influenza virus matrix protein-specific human T cell line with helper activity for in vitro anti-hemagglutinin antibody production. *European Journal of Immunology*, **1982**, 12, 844-9	6.1	19
60	Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 20753-20763	11.5	19
59	Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. *Cytokine*, **1996**, 8, 365-70	4	18
58	Interleukin 1 (IL-1) and tumour necrosis factor synergise in the induction of IL-1 synthesis by human vascular endothelial cells. *Immunology Letters*, **1988**, 19, 169-73	4.1	18
57	Macrophage-lymphocyte interactions in immune induction. *International Review of Cytology*, **1979**, 60, 149-78		18
56	Mechanism of antigenic competition. II. Induction by specific T cell products. *Cellular Immunology*, **1974**, 14, 255-69	4.4	18
55	Role of antigen structure in the discrimination between tolerance and immunity by b cells. *Immunological Reviews*, **1975**, 23, 78-97	11.3	16
54	RelB/p50 regulates CCL19 production, but fails to promote human DC maturation. *European Journal of Immunology*, **2009**, 39, 2215-23	6.1	15

53	Nature of macrophage-T cell interaction in secondary helper cell generation in vitro. Genetic restriction of macrophage-T cell interaction, which determines T-B genetic restriction. *European Journal of Immunology*, **1981**, 11, 377-81	6.1	15
52	Cellular basis of antibody production. *Quarterly Review of Biology*, **1972**, 47, 269-302	5.4	15
51	Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats. *FEBS Journal*, **1994**, 223, 831-40		13
50	The effects of tumor necrosis factor (TNF) derivatives on TNF receptors. *Cytokine*, **1993**, 5, 125-32	4	13
49	Role of epitope density in the induction of tolerance and immunity with thymus-independent antigens. III. Interaction of epitope density and receptor avidity. *European Journal of Immunology*, **1976**, 6, 646-50	6.1	13
48	Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis. *Science Advances*, **2019** , 5, eaay0370	14.3	12
47	Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?. *Novartis Foundation Symposium*, **2004**, 256, 53-69; discussion 69-73, 106-11, 266-9		11
46	Reversible blocking effect of anti-mouse immunoglobulin serum on the induction of immunity and tolerance in vitro. *Nature: New Biology*, **1971**, 231, 183-4		10
45	Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study. *Wellcome Open Research*, **2017**, 2, 37	4.8	10
44	Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B. *Journal of Immunology*, **2018**, 201, 1727-1734	5.3	9
43	A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma. *European Journal of Immunology*, **1987**, 17, 1441-6	6.1	9
42	A monoclonal antibody against antigen-specific helper factor augments T-cell help. *Nature*, **1983**, 301, 160-3	50.4	9
41	Relative affinity and avidity of the antigen-binding receptors of T and B rosette-forming cells. *Nature: New Biology*, **1973**, 245, 177-80		9
40	COVID-19 therapeutics: Challenges and directions for the future.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2119893119	11.5	9
39	Cellular census of human fibrosis defines functionally distinct stromal cell types and states. *Nature Communications*, **2020**, 11, 2768	17.4	7
38	Cannabinoids in Models of Chronic Inflammatory Conditions. *Phytochemistry Reviews*, **2005**, 4, 11-18	7.7	7
37	Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu. *Cancer Immunology, Immunotherapy*, **1996**, 42, 179-84	7.4	7
36	Antigen specific T cell factors. *Molecular and Cellular Biochemistry*, **1980**, 30, 177-93	4.2	7

35	Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course. *Scientific Reports*, **2020**, 10, 8830	4.9	6
34	Effect of soluble P55 tumour-necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions. *British Journal of Pharmacology*, **1996**, 117, 471-478	8.6	6
33	Direct evaluation of antigen binding to human T lymphocyte clones: involvement of major histocompatibility complex products in antigen binding. *European Journal of Immunology*, **1984**, 14, 1101-5	6.1	6
32	Lymphokines and interleukins emerge from the primeval soup. *Nature*, **1985**, 313, 351-2	50.4	6
31	Human T-cell responses in vitro: cell interactions and factors. *Annals of the New York Academy of Sciences*, **1979**, 332, 503-15	6.5	6
30	Complementation ofH-2-linkedIr genes: Use of helper factor to analyze responses to GLPhe. *Immunogenetics*, **1978**, 6, 471-481	3.2	6
29	The Detection of Autoantibody-Forming Cells. *International Archives of Allergy and Immunology*, **1972**, 42, 627-640	3.7	6
28	Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets. *Drug Discovery Today Disease Mechanisms*, **2004**, 1, 289-295		5
27	Interactions between autologous T cell clones. *Cellular Immunology*, **1990**, 128, 490-502	4.4	5
26	Comparison of antigen-specific I-region-associated cell interaction factors. *Annals of the New York Academy of Sciences*, **1979**, 332, 591-604	6.5	5
25	Collagen VI as a driver and disease biomarker in human fibrosis. *FEBS Journal*, **2021**,	5.7	5
24	Anti-TNF Therapy **2017**, 637-648		4
23	Specific interactions between a human CD4+ clone and autologous CD4+ bifunctional immunoregulatory clones. *Immunological Reviews*, **1990**, 116, 63-83	11.3	4
22	Single cell force profiling of human myofibroblasts reveals a biophysical spectrum of cell states. *Biology Open*, **2020**, 9,	2.2	4
21	Design and optimisation of bioactive cyclic peptides: generation of a down-regulator of TNF secretion. *Molecules*, **2014**, 19, 21529-40	4.8	3
20	The murine p75 TNF receptor promoter region: DNA sequence and characterization of a cis-acting silencer. *Molecular Immunology*, **1999**, 36, 125-34	4.3	3
19	Thymus-independent IgM and IgG responses in mice to flagellar antigens. *International Archives of Allergy and Immunology*, **1974**, 46, 600-11	3.7	3
18	Role of T-cell immunoglobulin in cell cooperation, T-cell suppression, and antigenic competition. *Annals of the New York Academy of Sciences*, **1975**, 249, 424-37	6.5	3

17	Gene therapy for rheumatoid arthritis?. *Journal of Clinical Investigation*, **2001**, 107, 1353	15.9	3
16	C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis.. *Nature Communications*, **2022**, 13, 215	17.4	3
15	Le TNF-□comme cible th□apeutique dans la polyarthrite rhumato□de : d□couverte, □udes pr□cliniques et cliniques. *Revue Du Rhumatisme (Edition Francaise)*, **2002**, 69, 12-19	0.1	2
14	Biochemical events initiated by exposure of human T lymphocyte clones to immunogenic and tolerogenic concentrations of antigen. *European Journal of Immunology*, **1985**, 15, 302-5	6.1	2
13	Cellular Interactions in Antibody Production. *Clinics in Rheumatic Diseases*, **1978**, 4, 481-498		2
12	Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function. *Frontiers in Immunology*, **2021**, 12, 626255	8.4	2
11	Host-targeting oral antiviral drugs to prevent pandemics.. *Lancet, The*, **2022**,	40	2
10	Targeting intracellular signaling: a novel approach to vaccination. *Expert Review of Vaccines*, **2007**, 6, 971-80	5.2	1
9	Comparison of peptide and superantigen-induced anergy in a peptide-specific polyclonal human T cell line. *International Immunology*, **1995**, 7, 1057-63	4.9	1
8	Antilipid A monoclonal antibody HA-1A decreases the capacity of bacterial lipopolysaccharide to activate human vascular endothelial cells by an immune adherence mechanism. *Cytokine*, **1993**, 5, 570-7	4	1
7	B cell stimulatory factor 2(BSF2/IL-6) and rheumatoid arthritis.. *Proceedings of the Japan Academy Series B: Physical and Biological Sciences*, **1987**, 63, 281-283	4	1
6	A vasculature niche orchestrates stromal cell phenotype through PDGF signaling: Importance in human fibrotic disease.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2120336119	11.5	1
5	Reply: To PMID 23784528. *Arthritis and Rheumatology*, **2014**, 66, 1962-3	9.5	
4	Potentiation of TNF-alpha toxicity by conjugation with ricin A-chain. *Cytokine*, **1998**, 10, 931-9	4	
3	CYTOKINES IN RHEUMATOID ARTHRITIS : IS TNF□OF HAAJOR IMPORTANCE?. *Clinical and Experimental Allergy*, **1993**, 23, 35-35	4.1	
2	Induction of autoimmunity: is there a role for infectious agents?. *Memorias Do Instituto Oswaldo Cruz*, **1987**, 82, 274-286	2.6	
1	Biological insights from clinical trials with anti-TNF therapy. *Seminars in Immunopathology*, **1998**, 20, 211-228		